Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) Net Margin: 2023-2025

Historic Net Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -972.95%.

  • Tonix Pharmaceuticals Holding's Net Margin fell 46930.00% to -972.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -963.38%, marking a year-over-year increase of 23447.00%. This contributed to the annual value of -1,288.25% for FY2024, which is 21353.00% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Net Margin stood at -972.95%, which was up 31.24% from -1,415.02% recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Net Margin ranged from a high of -503.65% in Q3 2024 and a low of -3,567.75% during Q2 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Net Margin value was -723.00% (recorded in 2023), while the average stood at -1,114.96%.
  • Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's Net Margin was 215,274bps (2025), while the steepest drop was 46,930bps (2025).
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Net Margin stood at -723.00% in 2023, then tumbled by 13,324bps to -856.24% in 2024, then slumped by 46,930bps to -972.95% in 2025.
  • Its Net Margin was -972.95% in Q3 2025, compared to -1,415.02% in Q2 2025 and -692.84% in Q1 2025.